Literature DB >> 16454743

Evolution of resistance to cancer therapy.

Franziska Michor1, Martin A Nowak, Yoh Iwasa.   

Abstract

Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16454743     DOI: 10.2174/138161206775201956

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  25 in total

1.  Dynamics of targeted cancer therapy.

Authors:  Ivana Bozic; Benjamin Allen; Martin A Nowak
Journal:  Trends Mol Med       Date:  2012-05-15       Impact factor: 11.951

Review 2.  The dynamics of drug resistance: a mathematical perspective.

Authors:  Orit Lavi; Michael M Gottesman; Doron Levy
Journal:  Drug Resist Updat       Date:  2012-03-03       Impact factor: 18.500

Review 3.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Authors:  Y Waerzeggers; R T Ullrich; P Monfared; T Viel; M Weckesser; W Stummer; O Schober; A Winkeler; A H Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

4.  The origins and implications of intratumor heterogeneity.

Authors:  Franziska Michor; Kornelia Polyak
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-19

5.  Stochastic dynamics of leukemic cells under an intermittent targeted therapy.

Authors:  Nicola Pizzolato; Dominique Persano Adorno; Davide Valenti; Bernardo Spagnolo
Journal:  Theory Biosci       Date:  2011-04-09       Impact factor: 1.919

6.  Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia cells.

Authors:  Onat Kadioglu; Thomas Efferth
Journal:  Invest New Drugs       Date:  2016-03-14       Impact factor: 3.850

Review 7.  Mathematical modeling as a tool for planning anticancer therapy.

Authors:  Andrzej Swierniak; Marek Kimmel; Jaroslaw Smieja
Journal:  Eur J Pharmacol       Date:  2009-10-13       Impact factor: 4.432

8.  Understanding the role of phenotypic switching in cancer drug resistance.

Authors:  Einar Bjarki Gunnarsson; Subhajyoti De; Kevin Leder; Jasmine Foo
Journal:  J Theor Biol       Date:  2020-01-14       Impact factor: 2.691

9.  Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution.

Authors:  Shaon Chakrabarti; Franziska Michor
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

Review 10.  Bioinformatics for cancer immunology and immunotherapy.

Authors:  Pornpimol Charoentong; Mihaela Angelova; Mirjana Efremova; Ralf Gallasch; Hubert Hackl; Jerome Galon; Zlatko Trajanoski
Journal:  Cancer Immunol Immunother       Date:  2012-09-18       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.